Company: QTIWW
Filing Date: 2025-12-29
Form Type: S-1/A
Source: 0001628280-25-058960
Chunk: 15

Company: QT IMAGING HOLDINGS, INC.
Filing Date: 2025-12-29
Form: S-1/A
Chunk 15
---
s”) because of its automation, small footprint, no shielding, no contrast-dye injection;

• the Company’s technology is portable and can be used in point-of-care (“POC”) settings such as LREs; and

<div align='center'>6</div>

• the Company’s technology is deployable in outdoor settings such as sports, military, and naval settings.

• The Company’s technology reduces the barriers to testing and follow up-care for women, as there is no need for specialized training and the technology is well-suited for lowering health care costs by being affordable and easily accessed.

• The Company’s technology provides optimized patient experience, as no radiation is involved, with the patient being able to be followed with no limitation to imaging frequency.

• The Company’s technology is well-suited for traditional tertiary care hospitals and additionally for direct to consumer (“ DTC ”) and direct to practitioner (“ DTP ”) applications, that are outside these institutions.

• The Company’s technology is uniquely proprietary, disruptive and a one-of-a kind product that can address a variety of unmet medical needs in the medical marketplace.

• The Company’s scanner features a uniquely simple design with a small number of components, which in turn significantly reduces the cost of the bill-of-materials (“ BOM ”), cost-of-goods-sold (“ COGS ”) , and the total-cost-of-ownership, and enables a lower average sales price (“ ASP ”) compared to other available systems, thus making it much more affordable to large mass deployments; and

• The Company’s products have potential strong revenue growth, with capital purchase or subscription-based recurring revenues supporting substantial long-term gross margin.

#### Our Strategies
We believe that our strategies include the following:

• Create disruptive technological innovation (software, artificial intelligence, and smart physics) to improve medical imaging and thus health care quality and access.

• Continue to improve our high quality, high resolution, native 3D, reproducible image quality regardless of operator or breast size/tissue type breast imaging technology, as well as the techniques for quantifiable analysis, comparison, and training.

• Build a biomarker-driven Cloud SaaS platform to shift from a hardware company to a precision imaging artificial intelligence platform combining hardware, software and cloud-based artificial intelligence modules. Biomarkers allow us to move beyond detection toward diagnostic and prognostic precision through quantitative imaging.

• Partner with strategic business and distribution channels to address U.S. market for breast imaging immediately and, other regions in the future, to place the QT Breast Scanner in hospitals